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ABSTRACT
Objectives: To investigate whether screening for
malnutrition using the validated malnutrition universal
screening tool (MUST) identifies specific characteristics
of patients at risk, in patients with gastro-entero-
pancreatic neuroendocrine tumours (GEP-NET).
Design: Cross-sectional study.
Setting: University Hospitals Coventry & Warwickshire
NHS Trust; European Neuroendocrine Tumour Society
Centre of Excellence.
Participants: Patients with confirmed GEP-NET
(n=161) of varying primary tumour sites, functioning
status, grading, staging and treatment modalities.
Main outcome measure: To identify disease and
treatment-related characteristics of patients with GEP-
NET who score using MUST, and should be directed to
detailed nutritional assessment.
Results: MUST score was positive (≥1) in 14% of
outpatients with GEP-NET. MUST-positive patients had
lower faecal elastase concentrations compared to
MUST-negative patients (244±37 vs 383±20 µg/g stool;
p=0.018), and were more likely to be on treatment with
long-acting somatostatin analogues (65 vs 38%,
p=0.021). MUST-positive patients were also more likely
to have rectal or unknown primary NET, whereas,
frequencies of other GEP-NET including pancreatic NET
were comparable between MUST-positive and MUST-
negative patients.
Conclusions: Given the frequency of patients
identified at malnutrition risk using MUST in our
relatively large and diverse GEP-NET cohort and the
clinical implications of detecting malnutrition early, we
recommend routine use of malnutrition screening in all
patients with GEP-NET, and particularly in patients who
are treated with long-acting somatostatin analogues.
INTRODUCTION
Malnutrition is caused by insufﬁcient delivery
of nutrients, or increased catabolism, and is
linked to major negative outcomes including
excess morbidity, mortality and higher treat-
ment costs.1–4 The prevalence of malnutri-
tion in patients with cancer has been
reported to range between 30% and 70%,
depending on tumour type, stage and treat-
ment modalities,5 but might be different in
patients with gastro-entero-pancreatic neu-
roendocrine tumours (GEP-NET).
GEP-NET comprise a complex group of
often slow-growing neoplasms that are
derived from primitive endocrine and neural
cells. The annual incidence of GEP-NET has
recently tripled to 40–50 cases per million,
which is thought to be at least, in part,
related to increased awareness and improved
diagnostic modalities.6 Malnutrition in
patients with GEP-NET might be frequent
for various reasons which include function-
ing tumours producing hormones that affect
gut transit,7–9 pancreatic masses, tumour
inﬁltration of the mesentery in midgut
Strengths and limitations of this study
▪ This study investigates the important clinical
problem of malnutrition screening in patients
with gastro-entero-pancreatic neuroendocrine
tumours (GEP-NET).
▪ Possible implications of the use of somatostatin
analogues on the risk of malnutrition in patients
with GEP-NET have not been reported in previ-
ous studies.
▪ Strengths of the study include the relatively large
size of a well characterised diverse cohort of
patients with GEP-NET, including information
about tumour grading, staging, functioning
status, biomarkers and treatment modalities.
▪ Limitations include the observational, real-world
nature of this study, with attendant limitations on
availability of data subsets and power in regres-
sion analyses.
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NET,10 11 prior abdominal surgery, or treatment with
somatostatin analogues.12–14
The National Institute for Health and Care Excellence
(NICE) recommends malnutrition screening in all adult
inpatients and outpatients in at-risk groups.2 Several
screening tools of varying complexity have been devel-
oped.5 The malabsorption universal screening tool
(MUST) is one of the more commonly used screening
methods in UK NHS Trusts, due to its simplicity and previ-
ous validation in multiple settings including use in patients
with cancer2 15–17 (ﬁgure 1). However, the potential utility
of malnutrition screening in patients with GEP-NET was
only reported in a single very recent study to date.18
Here, in a cohort of 161 patients with conﬁrmed
GEP-NET of varying primary tumour sites, grading,
staging, functioning status and treatment modalities, we
explored the prevalence of malnutrition, and whether
MUST-positive GEP-NET patients showed speciﬁc
disease or treatment-related characteristics.
MATERIALS AND METHODS
Participants and sample collection
The University Hospitals Coventry and Warwickshire
NHS Trust (UHCW) audit department approved the
study (audit number 1133/2015; July 2015). Data were
obtained from the local data base at the ARDEN NET
centre, European Neuroendocrine Tumour Society
(ENETS) Centre of Excellence (CoE) in UHCW. All
patients with GEP-NET who attend their routine clinical
appointments in the ARDEN NET Centre are screened
using MUST since May 2015; and were eligible for
inclusion.
Patients had physical examination as part of routine
clinical care and were characterised according to age,
gender, body weight, body height, body mass index
(BMI), the location of the primary tumour, staging,
histological grading (surgical sample or diagnostic
biopsy), presence or absence of functioning symptoms
(ie, ﬂushing or diarrhoea), treatment modalities
received, for example, treatment with somatostatin ana-
logues, information about prior abdominal surgery
GEP-NET-related or for any reason, and
GEP-NET-related biomarkers (most recent overnight
fasted gut hormone proﬁle from within the previous
6 months including Chromogranin A; other biomarkers
such as Chromogranin B, gastrin, vasoactive intestinal
polypeptide (VIP), somatostatin, glucagon and pancre-
atic polypeptide were available but only used for clinical
decision-making when appropriate. Samples for 24 h
urine were obtained following restriction of known
factors that can cause false high measurements of
Figure 1 Simplified scheme of use of the MUST score (adapted from BAPEN15). MUST was positive in 14.2% of the screened
patients (23/161 patients with GEP-NET). The majority of the patients with positive MUST scored 1 (n=14) or 2 (n=7), mostly
related to BMI <20 kg/m2 (n=16) and/or, less frequently, recent weight loss (n=9). Only n=2 of the patients in the entire cohort
had a MUST score of ≥3. MUST, malnutrition universal screening tool; GEP-NET, gastro-entero-pancreatic neuroendocrine
tumours; BMI, body mass index.
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urinary 5-HIAA. Further characteristics such as biomar-
kers for screening for exocrine pancreatic insufﬁciency
or heart failure were used if available for clinical
reasons. Using the available data a MUST score was cal-
culated. A simpliﬁed scheme of the use of the MUST
score is depicted in (ﬁgure 1).
Measurement of biomarkers
Routine biochemical markers were performed in the
biochemistry laboratory at UHCW. Plasma gut hormone
proﬁles were sampled after at least 10 h of overnight
fast. Analyses were performed by radioimmunoassay at
Hammersmith Hospital. Analyses for 5-HIAA were per-
formed using HPLC at Heartlands Hospital,
Birmingham. Faecal elastase-1 concentration in stools
was determined using an ELISA (ScheBo Pancreatic
Elastase-1 Stool Test), measured at City Hospital,
Birmingham, UK. The human faecal elastase-1 antibody
used here is immunologically speciﬁc and is not affected
by enzyme replacement therapies. A faecal elastase
concentration<200 µg/g stool indicates moderate, and a
concentration<100 µg/g stool indicates severe exocrine
pancreatic insufﬁciency.
Statistical analyses
Data are presented as mean±SE. Metric values were
tested for normal distribution using the Kolmogorov-
Smirnov test, and further analysed using the paired t
test. Non-normally distributed metric variables and ord-
inally scaled variables were analysed using the
Mann-Whitney U test. For nominally scaled variables, χ2
tests were applied. Ordinal data were correlated using
Spearman’s analyses (based on 1000 bootstrap samples)
to assess the associations between variables. Owing to
the relatively small number of patients in the respective
subgroups, all MUST-positive patients were pooled for
comparison with MUST-negative patients. Breusch
Pagan test and auxiliary regressions were used to investi-
gate for heteroscedasticity and signiﬁcant relationships
between ﬁtted predicted values and squared residuals.
Bootstrapped ordinal regression analyses (set as 1000
bootstrap samples) were performed with MUST score
(positive vs negative) as the dependent variable and age,
tumour stage, prior abdominal surgery (separately for
any prior abdominal surgery or GEP-NET-related
surgery, ie, ileocaecal resection or right hemicolectomy),
functioning status, treatment and duration of treatment
(in month) with somatostatin analogues and
GEP-NET-related biomarkers (normal or pathological)
as the independent variables, based on biological plausi-
bility to potentially cause malabsorption; bootstrapped p
values are provided. Backward stepwise binary logistic
regression analyses were additionally used to assess the
inﬂuence of individual variables on MUST score. A p
value<0.05 was considered statistically signiﬁcant. Data
analyses were performed using IBM SPSS Statistics V.22
(Chicago, Illinois, USA).
RESULTS
Baseline characteristics
MUST data were available in n=161 patients of the
GEP-NET cohort in the ARDEN NET centre. The cohort
comprised 74 men and 87 women. Age was 63.2
±1.2 years, body weight 75±1.4 kg, body height 167
±0.01 cm, BMI 26.7±0.4 kg/m2, and serum creatinine
85.1±3.5 µmol/L. Previous abdominal surgery for any
reason had been performed in n=96 (59.6%) of the
patients. Previous ileocaecal resection was done in n=17
(10.6%), and right hemicolectomy in n=14 (8.7%) of
the patients. Histological grading was available in n=133
(82.6%) of the patients, if performed for clinical
reasons; of those, n=86 (64.7%) had a grade 1 well dif-
ferentiated (G1) GEP-NET; n=32 (24.1%) had a grade 2
well differentiated (G2) GEP-NET; and n=15 (11.3%)
had a poorly differentiated (G3) neuroendocrine carcin-
oma of gastro-entero-pancreatic origin. Out of the 161
NET patients in this cohort, n=67 (41.6%) were on treat-
ment with somatostatin analogues (Sandostatin LAR
30 mg once monthly; or Somatuline Autogel 120 mg
once monthly); of those, n=43 (65.2%) had a well differ-
entiated midgut NET, and n=14 (21.2%) had a well dif-
ferentiated pancreatic NET. Mean duration of treatment
with somatostatin analogues in the n=67 treated patients
was 19.5±3.3 months at the time of data collection. Of
the 15 patients in the GEP NET cohort with pathological
faecal elastase concentrations (<200 µg/g stool; 96.1
±18.9 µg/g stool), n=12 had previous abdominal surgery
(any), n=7 had a pNET, n=3 had previous ileocaecal
resection, and n=1 had previous right hemicolectomy.
Further tumour characteristics of the cohort are shown
in (ﬁgure 2A–C).
Patients scoring positive using MUST
Fourteen per cent of the GEP-NET patients (n=23/161)
scored ≥1 using MUST, which classiﬁes the patient as
‘medium risk for malnutrition’, and should trigger a rec-
ommendation of ‘further observation’ of nutrition status
according to BAPEN/NICE guidelines;2 16 and 5.5% of
the patients scored ≥2 (n=9/161), which classiﬁes the
patient as ‘high risk for malnutrition’ and should trigger
treatment of malnutrition and, ideally, referral to the
dieticians or multidisciplinary nutrition team.16
Correlation analyses
Spearman analyses (based on 1000 bootstrap samples)
showed a moderate but statistically signiﬁcant negative
correlation of total MUST score (positive vs negative)
with faecal elastase concentrations (r=−0.32, p=0.005),
and a weak but statistically signiﬁcant positive correlation
with treatment with somatostatin analogues (r=0.20,
p=0.013). Duration of treatment with somatostatin analo-
gues showed a weak trend with total MUST score
(r=0.14; p=0.078). None of the remaining markers sig-
niﬁcantly correlated with MUST total score in boot-
strapped regression analyses, which included age,
gender, functioning status, tumour grade, tumour stage,
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biomarkers in blood and urine, serum creatinine, BNP,
prior abdominal surgery (any), and prior ileocaecal
resection or right hemicolectomy (all p>0.13).
Regression analyses
Bootstrapped binary logistic regression analyses in the
complete model identiﬁed use of somatostatin analo-
gues (exp (B)=0.022; 95% CI (0.000 to 1.554); p=0.004),
faecal elastase concentrations (exp (B)=0.992; 95% CI
(0.984 to 1.001); p=0.009)), age (exp (B)=0.901; 95% CI
(0.781 to 1.038; p=0.010) and tumour stage (≥T2;
p<0.044); and presence of distant metastatic disease M1
(p=0.037); but not N1) as signiﬁcant predictors of
MUST score. Duration of treatment with somatostatin
analogues was not a signiﬁcant predictor, neither in
bootstrapped nor in conventional analyses (p=0.11 and
p=0.63, respectively). The regression model was statistic-
ally signiﬁcant (χ2 26.58; p=0.046). The model explained
57% (Nagelkerke R2) of the variance in MUST, and cor-
rectly identiﬁed 95.5% of MUST-negative and 44.4% of
MUST-positive subjects.
To obtain additional information about the inﬂuence
of individual dependent variables, additional backward
stepwise binary logistic regression analyses were tested.
In step 6 of this stepwise model, again 44.4% of
MUST-positive patients and 97% of MUST-negative
patients were correctly identiﬁed, with use of
somatostatin analogues, but not other factors including
the duration of treatment with somatostatin analogues
remaining a statistically signiﬁcant predictor (p<0.001;
χ2 test 21.98, p=0.009), and explaining 49% (Nagelkerke
R2) of the variance in MUST. Again, duration of treat-
ment with somatostatin analogues did not inﬂuence the
variance in the MUST score (p>0.595 in all tested
models).
Use of somatostatin analogues (yes vs no) in boot-
strapped analyses with location of the primary tumour,
tumour grade, tumour stage and functioning status as
the independent variables was predicted by functioning
status (p=0.011), tumour grade (p<0.032) and presence
of distant metastases (M1, p=0.035), with location of the
primary tumour showing a trend. The model explained
55% of the variance in use of somatostatin analogues
and reasonably correctly predicted both treated (84.2%)
and untreated (78.3%) patients (χ2 66.35, p<0.001).
Characteristics of MUST-positive compared with
MUST-negative patients
Speciﬁc characteristics of GEP-NET patients with a positive
as compared with a negative MUST scores are shown in
(table 1). GEP-NET patients who scored ≥1 using MUST
were signiﬁcantly more frequently treated with somato-
statin analogues as compared with patients who did not
score using MUST (65% vs 38%; p=0.021) (table 1).
Figure 2 Characteristics of the
GEP-NET cohort. (A) location of
the primary tumour, (B)
distribution of tumour staging,
with the remaining 11.2% of the
patients being classified as Tx
(no signs of primary tumour), (C)
histological grading (well
differentiated, grade 1 and 2;
poorly differentiated, grade 3).
GEP-NET,
gastro-entero-pancreatic
neuroendocrine tumours.
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When stratifying the entire cohort according to treat-
ment with somatostatin analogues, 22.4% (n=15 of 67
patients) who were treated with somatostatin analogues
scored ≥1 using MUST, as compared to 8.5% (n=8 of 94
patients) who were not on treatment with somatostatin
analogues (p=0.013). MUST-positive patients showed sig-
niﬁcantly lower faecal elastase levels, as compared with
MUST-negative patients (table 1). Faecal elastase con-
centrations also tended to be lower in patients who were
on treatment with somatostatin analogues, as compared
with patients who were not on treatment with somato-
statin analogues (335±26 vs 402±27 µg/g stool; p=0.075).
Finally, patients who scored using MUST had signiﬁ-
cantly more often NET of the rectum or of unknown
origin, as compared with patients who did not score
(ﬁgure 3). Frequencies of midgut NET (p=0.688), pan-
creatic NET (p=0.195) and gastric NET (p=0.443) were
not signiﬁcantly different between MUST-positive and
MUST-negative patients (ﬁgure 3).
DISCUSSION
Malnutrition is an adjustable risk factor,19 but associated
with severe adverse clinical outcomes if not addressed.1 2
Patients with GEP-NET do not typically present with
major weight loss or acute illness before reaching the
very ﬁnal stages with extensive metastatic disease or car-
cinoid heart disease. This is related to the fact that
GEP-NET are often slower growing and less aggressive
tumours at least when well differentiated, as compared
with other types of cancer.20 Nevertheless, malnutrition
in patients with GEP-NET could be present for other
reasons, including chronic loose stools, osmotic diar-
rhoea,20 and excess secretion of serotonin precursors
stimulating small bowel motility.7–9 Pancreatic mass
effects, tumour inﬁltration of the mesentery10 11 and
GEP-NET-related treatment12–14 are further potential
risk factors.
In our outpatient cohort of patients with various types
of GEP-NET, 14% had a MUST score of >1, which should
trigger referral to the dietitians and the nutrition support
team.2 16 When comparing the cohort of patients who
scored using MUST with the patients who did not score,
we identiﬁed distinct characteristics of MUST-positive
patients with GEP-NET. MUST-positive patients were
more likely to have unknown primary or rectal NET,
which might be related to delayed diagnosis and wide-
spread disease in these patients. Furthermore,
MUST-positive patients showed signiﬁcantly lower faecal
elastase concentrations, although the frequency of pan-
creatic NET was not signiﬁcantly different between
groups, arguing against possible pancreatic mass effects
as the main driving factor. Most importantly,
MUST-positive patients were some twofold more likely to
be on treatment with long-acting somatostatin analogues.
After acute, short-term administration, rapid onset sup-
pression of pancreatic exocrine secretion by somatostatin
analogues21 22 and consequent steatorrhoea23 have been
reported. Further known mechanisms are in agreement
with a possible role of somatostatin analogues in convey-
ing malnutrition in patients with GEP-NET, although it is
important to mention that most previous reports refer to
effects of acute administration of somatostatin analo-
gues12 13 24 25 or in vitro studies,26 whereas effects after
chronic administration23 might be differently related to
possible adaptive mechanisms. Impairment of hepatic
bile acid physiology by somatostatin analogues has been
reported after both short-term27 and more prolonged
administration, and is causally involved in gallstone for-
mation.28 In the acute setting, intravenous somatostatin
inhibits glucose, triglyceride, amino acid and calcium
absorption by direct effects on the intestinal
mucosa;12 13 24 and decreases gastric acid secretion by
Figure 3 MUST-positive compared with MUST-negative
patients with GEP-NET. Patients who scored using MUST
were significantly more likely to have rectum NET (p<0.017)
or a NET with an unknown primary (p<0.017). Other types of
NET were not significantly different between MUST-positive
and MUST-negative patients, which included pancreatic NET
(p=0.195). Black bars: MUST-positive patients; grey bars:
MUST-negative patients. pNET, pancreatic neuroendocrine
tumour. MUST, malnutrition universal screening tool;
GEP-NET, gastro-entero-pancreatic neuroendocrine tumours;
NET, neuroendocrine tumours.
Table 1 Characteristics of MUST-positive compared with
MUST-negative patients with gastro-entero-pancreatic
neuroendocrine tumours of varying primaries, tumour
grading, staging and functioning status
MUST-positive
n=23
MUST-negative
n=138
p
Value
Treatment with
SSA (%)
65 38 0.021
Faecal elastase
(µg/g stool)
244±37 383±20 0.018
Data are given as mean±SE.
MUST, malnutrition universal screening tool; SSA, long-acting
somatostatin analogues.
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90% in healthy volunteers.24 In addition, acute suppres-
sion or in vitro effects of various gut hormones, such as
cholecystokinin and glucagon-like peptide-1 by somato-
statin analogues are well described,23 25 26 and diarrhoea,
steatorrhoea and weight loss are key features of excess
hormone-producing somatostatinomas.29 Possible impli-
cations of treatment with somatostatin analogues on
other aspects such as loss of fat-soluble vitamins in the
faeces have been also reported.30 It might be argued that
patients who were treated with long-acting somatostatin
analogues were more prone to score using MUST related
to functioning status and advanced disease progression,
as well as general risk factors such as age and
disease-related depression. However, treatment with som-
atostatin analogues remained a statistically signiﬁcant pre-
dictor of MUST in all tested models. Importantly,
duration of treatment with somatostatin analogues
showed no signiﬁcant inﬂuence in our analyses, indicat-
ing that acute effects of the administration of somato-
statin analogues on the likelihood scoring positive in the
MUST score were sustained after longer term treatment,
and somewhat arguing against adaptive mechanisms in
this context.
Our observed total rate of patients at risk of malnutri-
tion was somewhat lower than the prevalence very
recently reported by Maasberg et al18 in a neuroendo-
crine cohort of comparable size. Authors identiﬁed some
21%–25% of the patients at risk,18 as compared to 14%
in our study; however, the cohort in the mentioned study
comprised 87% inpatients and also included patients
with neuroendocrine tumours of the lung, as compared
with our study, which was exclusively assessed in outpati-
ents with GEP-NET. This may explain the lower frequency
of patients at risk of malnutrition in our cohort.
The observational nature of this study needs to be
mentioned as a limitation, as well as its relatively small
sample sizes when including not routinely measured bio-
markers in the regression models. Our study conﬁrms
the importance of screening for malnutrition in patients
with GEP-NET. This is directly clinically relevant, consid-
ering that malnutrition in patients with neuroendocrine
tumours could be an independent prognostic factor.18
Conﬁrmation of our ﬁndings in multicentre settings
with access to large and diverse GEP-NET patient
cohorts will be useful.
In summary, somatostatin analogues are key treatment
modalities in patients with well-differentiated GEP-NET,
but may cause transient or permanent gastrointestinal
side effects such as bloating and cramping in up to 30%
of the patients;31–33 and, based on our ﬁndings, appear to
increase malnutrition risk as identiﬁed by MUST. Without
systematically screening GEP-NET patients for malnutri-
tion, mild impairment of digestive processes might be
missed or attributed to functioning aspects of the
GEP-NET, rather than recognised and treated as a pos-
sible side effect of the treatment. Referring these patients
for early nutritional intervention could lead to improve-
ment of the nutritional status and quality of life.34
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32. Caplin ME, Pavel M, Ćwikła JB, et al. Lanreotide in metastatic
enteropancreatic neuroendocrine tumors. N Engl J Med
2014;371:224–33.
33. Rinke A, Müller HH, Schade-Brittinger C, et al. Placebo-controlled,
double-blind, prospective, randomized study on the effect of
octreotide LAR in the control of tumor growth in patients with
metastatic neuroendocrine midgut tumors: a report from the
PROMID Study Group. J Clin Oncol 2009;27:4656–63.
34. Paccagnella A, Morassutti I, Rosti G. Nutritional intervention for
improving treatment tolerance in cancer patients. Curr Opin Oncol
2011;23:322–30.
Qureshi SA, et al. BMJ Open 2016;6:e010765. doi:10.1136/bmjopen-2015-010765 7
Open Access
group.bmj.com on March 21, 2018 - Published by http://bmjopen.bmj.com/Downloaded from 
tumours: a cross-sectional study
gastro-entero-pancreatic neuroendocrine 
Screening for malnutrition in patients with
S Randeva, Georgios K Dimitriadis and Martin O Weickert
Louise Davies, Simon Fletcher, William Shatwell, Sharmila Sothi, Harpal 
Wong,Saboor Khan, Kishore Gopalakrishnan, Catherine Darby, John L H 
Sheharyar A Qureshi, Nicola Burch, Maralyn Druce, John G Hattersley,
doi: 10.1136/bmjopen-2015-010765
2016 6: BMJ Open
 http://bmjopen.bmj.com/content/6/5/e010765
Updated information and services can be found at: 
These include:
References
 http://bmjopen.bmj.com/content/6/5/e010765#ref-list-1
This article cites 28 articles, 5 of which you can access for free at: 
Open Access
http://creativecommons.org/licenses/by-nc/4.0/non-commercial. See: 
provided the original work is properly cited and the use is
non-commercially, and license their derivative works on different terms, 
permits others to distribute, remix, adapt, build upon this work
Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
This is an Open Access article distributed in accordance with the Creative
service
Email alerting
box at the top right corner of the online article. 
Receive free email alerts when new articles cite this article. Sign up in the
Collections
Topic Articles on similar topics can be found in the following collections 
 (466)Oncology
 (346)Nutrition and metabolism
 (456)Diabetes and Endocrinology
Notes
http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
http://journals.bmj.com/cgi/reprintform
To order reprints go to:
http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
group.bmj.com on March 21, 2018 - Published by http://bmjopen.bmj.com/Downloaded from 
